RESUMO
AIMS: To evaluate the effects of therapeutic and supratherapeutic doses of rupatadine on cardiac repolarization in line with a 'thorough QT/QTc study' protocol performed according to International Conference on Harmonization guidelines. METHODS: This was a randomized (gender-balanced), parallel-group study involving 160 healthy volunteers. Rupatadine, 10 and 100 mg day(-1), and placebo were administered single-blind for 5 days, whilst moxifloxacin 400 mg day(-1) was given on days 1 and 5 in open-label fashion. ECGs were recorded over a 23-h period by continuous Holter monitoring at baseline and on treatment days 1 and 5. Three 10-s ECG samples were downloaded at regular intervals and were analysed independently. The primary analysis of QTc was based on individually corrected QT (QTcI). Treatment effects on QTcI were assessed using the largest time-matched mean difference between the drug and placebo (baseline-subtracted) for the QTcI interval. A negative 'thorough QT/QTc study' is one where the main variable is around < or =5 ms, with a one-sided 95% confidence interval that excludes an effect >10 ms. RESULTS: The validity of the trial was confirmed by the fact that the moxifloxacin-positive control group produced the expected change in QTcI duration (around 5 ms). The ECG data for rupatadine at both 10 and 100 mg showed no signal effects on the ECG, after neither single nor repeated administration. Furthermore, no pharmacokinetic/pharmacodynamic relationship, gender effects or clinically relevant changes in ECG waveform outliers were observed. No deaths or serious or unexpected adverse events were reported. CONCLUSIONS: This 'thorough QT/QTc study' confirmed previous experience with rupatadine and demonstrated that it had no proarrhythmic potential and raised no concerns regarding its cardiac safety.
Assuntos
Antialérgicos/farmacologia , Ciproeptadina/análogos & derivados , Eletrocardiografia/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Antagonistas não Sedativos dos Receptores H1 da Histamina/farmacologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Adolescente , Adulto , Ciproeptadina/farmacologia , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Adulto JovemRESUMO
BACKGROUND: Rupatadine is an oral active antihistamine and platelet-activating factor antagonist indicated for the management of allergic rhinitis and chronic urticaria in Europe. OBJECTIVE: The purpose of this study was to describe the effect of the concomitant administration of azithromycin and rupatadine on the pharmacokinetics of rupatadine and its metabolites after repeated doses. METHODS: This was a multiple-dose, randomized, open-label, 2-way, crossover, Phase I study in which healthy male and female volunteers received rupatadine 10 mg once a day for 6 days either alone or with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6. Treatments were administered after a fasting period of 10 hours with 240 mL of water, and fasting conditions were kept until 3 hours postmedication. A washout period of at least 21 days between the 2 active periods was observed. Blood samples were collected and plasma concentrations of rupatadine and its metabolites desloratadine and 3-hydroxydesloratadine were determined by liquid chromatography tandem mass spectrometry. Tolerability was based on the recording of adverse events (AEs), physical examination, electrocardiograms, and laboratory screen controls at baseline and the final study visit. RESULTS: Twenty-four healthy volunteers (15 males, 9 females; mean [SD] age, 25.67 [5.58] years; weight, 65.96 [8.57] kg) completed the study. Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone. The Cmax,ss ratio was 111 (90% CI, 91-136) and area under the plasma concentration-time curve during a dosing interval (AUC0-tau) ratio had a value of 103 (90% CI, 91-117). The corresponding ratios for the rupatadine metabolites were 109 (90% CI, 100-120) for Cmax,ss and 103 (90% CI, 96-110) for AUC0-tau for desloratadine and 109 (90% CI, 103-115) for Cmax,ss and 104 (90% CI, 100-108) for AUC0-tau for 3-hydroxydesloratadine. Point estimates for Cmax,ss ratios using paired data were 111% for rupatadine, 109% for desloratadine, and 109% for 3-hydroxydesloratadine. The 90% CIs were included in the interval 80% to 125% for desloratadine and 3-hydroxydesloratadine, whereas 90% CI for rupatadine was shifted to the right of the interval used for comparing bioavailability of the drugs. A total of 5 subjects reported 9 AEs; 5 of these were thought to be related to the drug administration and all were categorized as mild or moderate. The reported AEs were somnolence (1/24 in the rupatadine group and 1/24 in the rupatadine plus azithromycin group), diarrhea (1/24 in the rupatadine plus azithromycin group), and gastric discomfort (2/24 in the rupatadine plus azithromycin group). Four AEs were considered not to be related (2 episodes of headache, 1 anemia, 1 cheilitis). All were resolved spontaneously. No serious AEs were reported. CONCLUSIONS: The results of this study in these healthy volunteers found no significant differences in pharmacokinetic parameters other than Cmax,ss of 3-hydroxydesloratadine between rupatadine 10 mg administered alone or with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6. The administration of rupatadine compared with rupatadine plus azithromycin met the regulatory definition of bioequivalence in terms of exposure and rate parameters; however, Cmax,ss of rupatadine was outside the conventional confidence interval.
Assuntos
Antibacterianos/farmacologia , Azitromicina/farmacologia , Ciproeptadina/análogos & derivados , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Loratadina/farmacocinética , Administração Oral , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Área Sob a Curva , Azitromicina/administração & dosagem , Azitromicina/efeitos adversos , Cromatografia Líquida de Alta Pressão , Intervalos de Confiança , Estudos Cross-Over , Ciproeptadina/administração & dosagem , Ciproeptadina/efeitos adversos , Ciproeptadina/farmacocinética , Relação Dose-Resposta a Droga , Interações Medicamentosas , Feminino , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Humanos , Loratadina/administração & dosagem , Loratadina/efeitos adversos , Loratadina/análogos & derivados , Loratadina/sangue , Masculino , Segurança , Equivalência TerapêuticaRESUMO
Rupatadine is a new oral antihistaminic agent used for the management of allergic inflammatory conditions, such as rhinitis and chronic urticaria. The aim of the present study was to develop a population pharmacokinetic/pharmacodynamic (PKPD) model for the description of the effect of rupatadine and one of its active metabolites, desloratadine, on the histamine-induced flare reaction and to predict the response to treatment after repeated administrations of rupatadine. Both rupatadine and desloratadine were characterized by two-compartmental kinetics. For both compounds, covariates sex and weight had a significant effect on several parameters. The pharmacodynamics were described by an indirect model for the inhibition of flare formation that accounted for the contribution of both rupatadine and desloratadine to the antihistaminic effect. The final PKPD model adequately described the original data. The simulated response after repeated once-daily administrations of 10 mg rupatadine showed a significant and maintained antihistaminic effect over time, between two consecutive dosing intervals.
Assuntos
Ciproeptadina/análogos & derivados , Antagonistas dos Receptores Histamínicos/farmacologia , Antagonistas dos Receptores Histamínicos/farmacocinética , Adulto , Algoritmos , Biotransformação , Ciproeptadina/farmacocinética , Ciproeptadina/farmacologia , Feminino , Humanos , Loratadina/sangue , Masculino , Modelos Estatísticos , População , Fatores SexuaisRESUMO
BACKGROUND: Rupatadine is an oral active antihistamine for the management of diseases with allergic inflammatory conditions, such as perennial and seasonal rhinitis and chronic idiopathic urticaria. Oral rupatadine has been approved for the treatment of allergic rhinitis and chronic urticaria in adults and adolescents in several European countries. OBJECTIVE: The purpose of this study was to describe the effect of the concomitant intake of food on the pharmacokinetic profile and bioavailability of a single dose of rupatadine. METHODS: This was a single-dose, randomized, open-label, 2-way crossover study in which healthy male and female volunteers received a single, 20-mg oral dose of rupatadine under fed and fasting conditions. Blood samples were collected and plasma concentrations of rupatadine and its active metabolites desloratadine and 3-hydroxydesloratadine were determined by liquid chromatography tandem mass spectrometry. Tolerability was based on the recording of adverse events (AEs), physical examinations, electrocardiograms, and laboratory tolerability tests immediately before each treatment period and at the final visit of the study. RESULTS: Twenty-four volunteers (12 males; mean [SD] age, 25.4 [5.3] years [range, 18-34 years]; mean [SD] weight, 71.2 [4.3] kg [range, 64-77 kg]; 12 females; mean [SD] age, 26.8 [6.5] years [range, 18-38 years]; mean [SD] weight, 58.4 [6.8] kg, [range 50-69 kg]) were enrolled and randomized with equal distribution of sex. A significant increase in AUC from drug administration to the final quantifiable sample (AUC(0-t)) and AUC from drug administration to infinity (AUC(0-infinity)) values of rupatadine was seen under fed conditions without affecting C(max). The ratios (90% CI) of the mean log-transformed AUC(0-t) and AUC(0-infinity) for rupatadine revealed a significant increase in AUC(0-t) (ratio 131%; 90% CI, 111%-154%) and AUC(0-infinity) (ratio 133%; 90% CI, 113%-156%), whereas C(max) remained unaltered (ratio 97%; 90% CI, 80%-116%). Plasma concentration-time profiles of desloratadine and 3-hydroxydesloratadine were similar with and without food, and no differences were seen for AUC(0-t), AUC(0-infinity), or C(max). Seven (28%) subjects reported > or =1 AE. All AEs were mild, resolved spontaneously, and did not affect the outcome of the study. CONCLUSIONS: The results of this study indicate that concomitant intake of food with a single 20-mg oral dose of rupatadine exhibits a significant increase in rupatadine bioavailability. Despite the absence of bioequivalence, the drug was well tolerated under fed and fasting conditions, and no major changes in severity and/or prevalence of AEs were reported.
Assuntos
Ciproeptadina/análogos & derivados , Interações Alimento-Droga , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Adolescente , Adulto , Área Sob a Curva , Disponibilidade Biológica , Estudos Cross-Over , Ciproeptadina/administração & dosagem , Ciproeptadina/farmacocinética , Feminino , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Humanos , Loratadina/análogos & derivados , Loratadina/sangue , Loratadina/farmacocinética , Masculino , ComprimidosRESUMO
Se realizó un estudio descriptivo transversal para conocer el comportamiento de los factores de riesgo de toxemia en embarazadas atendidas en los consultorios del médico y la enfermera de la familia de la Policlínica Comunitaria Docente Rodolfo Ramírez Esquivel durante el año 2002. El universo estuvo constituido por 54 gestantes, se aplicó una encuesta con las siguientes variables: tiempo de gestación al diagnóstico, antecedentes patológicos personales, antecedentes familiares de madres eclámpticas, antecedentes obstétricos y estado nutricional materno. Como resultado del trabajo se detectó que el tiempo de gestación de 31 a 33 semanas fue el más frecuente (51.9 por ciento) para el diagnóstico de toxemia. La no presencia de antecedentes patológicos personales (70.3 por ciento) y obstétricos (61.1 por ciento) predominaron en el estudio. El bajo peso, con un 44.4 por ciento, y la no presencia de antecedentes familiares de madres eclámpticas con un 74 por ciento, aparecieron con mayor frecuencia
Assuntos
Feminino , Gravidez , Humanos , Eclampsia , Atenção Primária à Saúde , Pré-Eclâmpsia/diagnóstico , Pré-Eclâmpsia/patologia , Fatores de Risco , Estudos Transversais , Epidemiologia DescritivaRESUMO
Se realizó un estudio descriptivo transversal para conocer el comportamiento de los factores de riesgo de toxemia en embarazadas atendidas en los consultorios del médico y la enfermera de la familia de la Policlínica Comunitaria Docente Rodolfo Ramírez Esquivel durante el año 2002. El universo estuvo constituido por 54 gestantes, se aplicó una encuesta con las siguientes variables: tiempo de gestación al diagnóstico, antecedentes patológicos personales, antecedentes familiares de madres eclámpticas, antecedentes obstétricos y estado nutricional materno. Como resultado del trabajo se detectó que el tiempo de gestación de 31 a 33 semanas fue el más frecuente (51.9 por ciento) para el diagnóstico de toxemia. La no presencia de antecedentes patológicos personales (70.3 por ciento) y obstétricos (61.1 por ciento) predominaron en el estudio. El bajo peso, con un 44.4 por ciento, y la no presencia de antecedentes familiares de madres eclámpticas con un 74 por ciento, aparecieron con mayor frecuencia(AU)
Assuntos
Humanos , Feminino , Gravidez , Pré-Eclâmpsia/diagnóstico , Pré-Eclâmpsia/patologia , Fatores de Risco , Atenção Primária à Saúde , Eclampsia , Epidemiologia Descritiva , Estudos TransversaisRESUMO
Com o intuito de contribuir para o estudo das funções da enfermeira da saúde pública, face à situação que a enfermagem nesse campo apresenta no Brasil, aos escassos estudos existentes sobre o assunto e às necessidades sanitárias do País, a autora realizou uma pesquisa em dois municípios do Estado de São Paulo. O trabalho analisa detidamente a situação da enfermagem de saúde pública no Estado de São Paulo, citado as disposições vigentes no País, que ás vezes são observadas, em prejuízo do profissional e do atendimento de enfermagem dispensado à população. A autora, também, ressalta a importância da atuação da enfermeira de saúde pública e a necessidade que a população sente de seus serviços. Finalmente, o trabalho apresenta sugestões visando atender adequadamente às necessidades da população com relação a serviços de enfermagem (AU).